EXCERPT:
Gilead is acquiring Arcellx outright for $7.8 billion, bringing the BCMA-directed CAR-T therapy anitocabtagene autoleucel fully under Gilead’s Kite unit. The deal reflects continued big pharma confidence in cell therapy despite manufacturing complexity.
CONTENT:
Gilead Sciences has agreed to acquire Arcellx for $7.8 billion, giving the company full control of anitocabtagene autoleucel — a BCMA-directed CAR-T cell therapy for relapsed or refractory multiple myeloma that the two companies had been co-developing through Kite, Gilead’s cell therapy arm.
The acquisition consolidates what was already a close partnership into a single owner, simplifying the commercial and development path for a therapy that has shown strong clinical results. For the CAR-T field, the deal is another signal that large pharma views cell therapy not as a niche play but as a core growth driver worth multi-billion-dollar commitments.
The manufacturing angle here is significant. CAR-T remains one of the most operationally complex modalities to scale — autologous processes, tight vein-to-vein timelines, cryopreservation logistics, and rigorous release testing. CROs and CDMOs with cell therapy infrastructure will continue to see demand from programs like this as more therapies approach or enter commercial scale.